Loading quotes...

Forecast

Buy	8
Hold	10
Sell	0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

News Go to news feed

Abiomed wins patent case against Maquet in Massachusetts

A jury in Massachusetts found that Abiomed’s intravascular Impella heart pumps did not infringe a Maquet patent and declared the patent invalid. Abiomed is part of Johnson & Johnson, which completed the acquisition in 2022 for $16.6 billion; Abiomed’s products generated around $1.75 billion in worldwide sales in 2025. The lawsuit dates back to 2017; the Impella models have previously been subject to several FDA recalls. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2022, Abiomed has already paid €0.26 in dividends. The last payout was in March 2022.

Financials

In the last year, Abiomed had revenue of €931.86m and net profit of €123.29m

(EUR)	2022	YoY
Revenue	931.86m	28.93%
Gross profit	761.92m	30.32%
Net profit	123.29m	35.89%
EBITDA	452.01m	114.65%

Fundamentals

Metric	Value
Market capitalization	€15.58bn
Number of shares	45.09m
52-week high/low	€346.48 - €199.41
Dividends	No
Beta	0.00
P/E ratio	127.01
PEG ratio	1.61
P/B ratio	11.52
P/S ratio	16.65

Company profile

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.